[CINCINNATI, OH, JUNE 16, 2015] – Schulman Associates IRB, Inc., the industry-leading central IRB in customer service and technology, announces the acquisition of Missouri-based Absolute Research. Additionally, Absolute Research founder Rebecca Ballard will be joining the Schulman team as Vice President of Compliance and Board Operations.
The transaction allows for significant investment to expand Absolute Research’s innovative technology offerings for the clinical research community, and Ms. Ballard’s substantial research ethics and legal expertise, as well as her leadership experience in the institutional research setting, bring valuable perspectives and knowledge to the organization.
“We are thrilled to join forces with Absolute Research and Rebecca Ballard,” said Michael Woods, President and CEO at Schulman. “Ms. Ballard’s talents and expertise and the tools she has developed through Absolute Research provide strategic advantages never seen before in the research community and will offer Schulman’s sponsor, CRO, site and institutional clients unparalleled efficiencies in clinical research conduct.”
Absolute Research’s technology offerings, including Animated Consent and Absolute Core, will be branded through Schulman’s joint venture Provision Research Compliance Services. Ms. Ballard will join Schulman’s staff in September 2015.
About Schulman Associates IRB, Inc.
Schulman Associates IRB has been a leader in the protection of human research participants in the U.S., Puerto Rico and Canada since 1983. Schulman offers thorough, timely IRB review services – including dedicated review capabilities for all phases of research across all therapeutic areas – to clinical trial sponsors, CROs, investigators and institutions. Schulman also provides global consulting services through its joint venture partner Provision Research Compliance Services, offering comprehensive solutions to improve overall quality standards for clinical studies and data integrity, and to maximize the protection of human subjects. Fully accredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP), Schulman has an unparalleled clean audit history with the Food and Drug Administration (FDA).
For more information, please visit http://www.sairb.com or follow @SchulmanIRB on Twitter or on LinkedIn.
Final ENLIVEN Trial Results Confirm Long-Term Benefit of Turalio in Tenosynovial Giant Cell Tumor
July 9th 2025In final data from the Phase III ENLIVEN study, Turalio (pexidartinib) demonstrated durable tumor responses and a consistent safety profile in patients with symptomatic TGCT not amenable to surgery.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.
Effect of AI/ML, Real World Evidence and Master Protocols on Trial Success
July 7th 2025How the application of artificial intelligence, broader use of real-world evidence, decentralized clinical trials, master protocols, and risk-based quality monitoring, together with strong ethical oversight and increased collaboration, are contributing to better healthcare delivery and strengthening the role of clinical research in driving global health progress.